Pricing Log in Create free account

Apimeds Pharmaceuticals US, Inc. (APUS) vs IM Cannabis Corp. (IMCC)

Apimeds Pharmaceuticals US, Inc. and IM Cannabis Corp. are both Drug Manufacturers Specialty & Generic companies. Apimeds Pharmaceuticals US, Inc. is the larger, with a market value of $4.1M against $980.0K — 4.2× the size. Apimeds Pharmaceuticals US, Inc. has the higher net margin (0.00% vs −38.9%) and the lower return on invested capital (−16.0% vs 0.00%). Across the 12 metrics below, IM Cannabis Corp. leads on 8 and Apimeds Pharmaceuticals US, Inc. on 4.

Valuation

Metric APUS IMCC Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.55
P/S n/m 0.01 2.08
P/B 0.04 n/m 1.79
Price to free cash flow n/m n/m 16.29
EV/EBITDA n/m 0.01 12.22
EV/Sales n/m 0.00 2.87
Earnings yield (1,394.72%) (13,047.81%) (15.94%)
Free cash flow yield (295.94%) (267.31%) 0.00%

Profitability

Metric APUS IMCC Drug Manufacturers Specialty & Generic median
Gross margin — 12.62% 53.51%
Operating margin 0.00% (32.88%) 0.00%
Net margin 0.00% (38.92%) (2.45%)
Free cash flow margin 0.00% (1.47%) 0.00%
Return on equity (100.13%) 2,280.06% (0.80%)
Return on assets (84.20%) (54.20%) (1.67%)
Return on invested capital (15.96%) 0.00% 0.00%

Growth

Metric APUS IMCC Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) — (11.97%) 5.22%
EPS growth (last fiscal year) (205.56%) 41.95% 42.91%
Revenue growth, 5-year CAGR — 26.99% 7.24%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric APUS IMCC Drug Manufacturers Specialty & Generic median
Debt to equity 0.08 (0.12) 0.04
Current ratio 0.51 0.56 2.41
Net debt to EBITDA 0.38 0.18 1.01

Dividend

Metric APUS IMCC Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.45%
Payout ratio — — 0.27

Size

Metric APUS IMCC Drug Manufacturers Specialty & Generic median
Market cap 4.12m 980.00k 315.39m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack